Prepregnancy Diabetes and Offspring Risk of Congenital Heart Disease:A Nationwide Cohort Study by Øyen, Nina et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Prepregnancy Diabetes and Offspring Risk of Congenital Heart Disease
Øyen, Nina; Diaz, Lars Jorge; Leirgul, Elisabeth; Boyd, Heather A; Priest, James; Mathiesen,
Elisabeth R; Quertermous, Thomas; Wohlfahrt, Jan; Melbye, Mads
Published in:
Circulation
DOI:
10.1161/CIRCULATIONAHA.115.017465
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Øyen, N., Diaz, L. J., Leirgul, E., Boyd, H. A., Priest, J., Mathiesen, E. R., ... Melbye, M. (2016). Prepregnancy
Diabetes and Offspring Risk of Congenital Heart Disease: A Nationwide Cohort Study. Circulation, 133(23),
2243-2253. https://doi.org/10.1161/CIRCULATIONAHA.115.017465
Download date: 03. Feb. 2020
2243
Women with diabetes mellitus have considerably higher risks of adverse pregnancy outcomes, including birth 
defects, than nondiabetic women,1–3 and pregestational mater-
nal diabetes mellitus is the only relatively prevalent population 
risk factor for congenital heart defects (CHDs).4 Even though 
the association of pregestational diabetes mellitus with CHD 
has been known for decades, it is not clear if this knowledge has 
resulted in a substantive impact of the reduction of pregnancies 
complicated by diabetes mellitus or in the proportion of births 
with CHDs attributable to pregestational diabetes mellitus.
Editorial, see p 2219  
Clinical Perspective on p 2253
Experimental studies suggest that hyperglycemia during 
early embryogenesis may alter gene expression in key cel-
lular components of the developing heart, in particular, the 
embryonic heart’s outflow sections; however, the mechanism 
producing this altered gene expression is unclear.5–9 Maternal 
diabetes mellitus may be associated with specific types of 
CHD, yet epidemiological studies published to date have not 
focused specifically, finding the effect of diabetes mellitus to 
differ across sections of the embryonic heart corresponding to 
cardiac phenotypes.1,3,10–13 In addition, associations may differ 
for type 1 and type 2 diabetes mellitus, which would offer 
insight into possible teratogenic mechanisms.
Background—Maternal diabetes mellitus is associated with an increased risk of offspring congenital heart defects (CHD); 
however, the causal mechanism is poorly understood. We further investigated this association in a Danish nationwide cohort.
Methods and Results—In a national cohort study, we identified 2 025 727 persons born from 1978 to 2011; among them were 
7296 (0.36%) persons exposed to maternal pregestational diabetes mellitus. Pregestational diabetes mellitus was identified by 
using the National Patient Register and individual-level information on all prescriptions filled in Danish pharmacies. Persons 
with CHD (n=16 325) were assigned to embryologically related cardiac phenotypes. The CHD prevalence in the offspring of 
mothers with pregestational diabetes mellitus was 318 per 10 000 live births (n=232) in comparison with a baseline risk of 80 per 
10 000; the adjusted relative risk for CHD was 4.00 (95% confidence interval, 3.51–4.53). The association was not modified by 
year of birth, maternal age at diabetes onset, or diabetes duration, and CHD risks associated with type 1 (insulin-dependent) and 
type 2 (insulin-independent) diabetes mellitus did not differ significantly. Persons born to women with previous acute diabetes 
complications had a higher CHD risk than those exposed to maternal diabetes mellitus without complications (relative risk, 
7.62; 95% confidence interval, 5.23–10.6, and relative risk, 3.49; 95% confidence interval, 2.91–4.13, respectively; P=0.0004). 
All specific CHD phenotypes were associated with maternal pregestational diabetes mellitus (relative risk range, 2.74–13.8).
Conclusions—The profoundly increased CHD risk conferred by maternal pregestational diabetes mellitus neither changed 
over time nor differed by diabetes subtype. The association with acute pregestational diabetes complications was 
particularly strong, suggesting a role for glucose in the causal pathway.  (Circulation. 2016;133:2243-2253. DOI: 
10.1161/CIRCULATIONAHA.115.017465.)
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In this Danish nationwide cohort study, we investigated 
the risk of CHDs in the offspring of women with pregesta-
tional diabetes mellitus. In addition, we investigated whether 
(1) the association has changed over time, (2) pregestational 
diabetes complications further increased the risk of CHD, (3) 
the association was linked to specific CHDs, and (4) the asso-
ciation varied by maternal diabetes type.
Methods
Data Sources
Since 1968, the Danish Civil Registration System has registered 
demographic, vital status, and kinship information on all persons in 
Denmark, using the unique personal identification number assigned 
to each Danish resident.14 The personal identification number permits 
accurate linkage of individual-level information from Denmark’s 
nationwide registers, including the National Patient Register (NPR),15 
the Medical Birth Register,16 the Abortion Register,17 the Causes of 
Death Register, the Register of Medicinal Product Statistics,18 and the 
Danish Cytogenetic Central Register (postnatal diagnoses since 1968, 
prenatal diagnoses since 1978).
Study Cohort
Our study cohort included all singletons born alive in Denmark 
between 1978 and 2011, identified via the Civil Registration System. 
Persons with chromosomal aberrations (identified by using the 
Cytogenetic Central Register) or birth defects with recognizable syn-
dromes or known causes (identified by using the NPR, International 
Classification of Diseases, 10th Revision (ICD-10) codes Q85, Q86, 
Q87, Q75.1, Q75.4, Q77.1, Q77.2, Q79.6, Q44.7B, Q61.9A), and 
those whose mother had a CHD, were excluded from the cohort.
Identification of Maternal Pregestational Diabetes 
Mellitus
We identified each cohort member’s mother using the Civil 
Registration System and determined which of these women had pre-
gestational diabetes mellitus by using the NPR. We defined pregesta-
tional diabetes mellitus as pregestational registration of International 
Classification of Diseases, 8th Revision (ICD-8) codes 250 or 249, or 
ICD-10 codes E10.0 to E11.9.
Diabetes coding in the NPR has changed over time, with a single 
diabetes code (250) in the period 1977 to 1986, codes for insulin-
dependent (249) and insulin-independent (250) diabetes mellitus from 
1987 to 1993, and codes for type 1 (E10) and type 2 (E11) diabetes 
mellitus from 1994 onward. Preliminary analyses revealed that 39% 
of the mothers with pregestational diabetes mellitus had codes for 
both type 1/insulin-dependent and type 2/insulin-independent diabe-
tes mellitus. We therefore defined type 1 and type 2 diabetes mellitus 
by using 2 approaches (timing of disease onset, first-time antidiabetic 
treatment). First, we used maternal age at diagnosis <30 years and 
≥30 years as cut-offs for type 1 and type 2 diabetes mellitus, respec-
tively.19,20 Second, for births, 1996 to 2011, we retrieved Register 
of Medicinal Product Statistics (established 1994) information, on 
first-time maternal prescriptions for insulin (Anatomic Therapeutic 
Chemical classification system code A10A) and oral antidiabetic 
medications (Anatomic Therapeutic Chemical code A10B) for moth-
ers with NPR-defined pregestational diabetes mellitus.
Diabetic complications may reflect poor glycemic control. 
Therefore, we also used NPR to identify mothers with pregesta-
tional diabetes mellitus who had diabetic complications before 
pregnancy. We defined coma (ICD-8 codes 249.06, 249.07, 250.06, 
250.07; ICD-10 codes E10.0, E11.0) and ketoacidosis (ICD-10 codes 
E10.1, E11.1) as acute complications, and nephropathy (ICD-8 codes 
249.02, 250.02; ICD-10 codes E10.2, E11.2), retinopathy (ICD-8 
codes 249.01, 250.01; ICD-10 codes E10.3, E11.3, H36.0–H36.9), 
neuropathy (ICD-8 codes 249.03, 250.03; ICD-10 codes E10.4, 
E11.4), vasculopathy/angiopathy (ICD-8 codes 249.04, 249.05, 
250.04, 250.05; ICD-10 codes E10.5, E11.5), and other defined dia-
betic complications (ICD-8 codes 249.08, 250.08; ICD-10 codes 
E10.6, E11.6, E10.8, E11.8,) as late complications. Women were 
either classified as having a single complication or ≥2 complications, 
where the latter was defined as multiple complications (ICD-10 codes 
E10.7, E11.7) or registration of ≥2 of the above complications. In an 
alternate categorization scheme, women were classified as having ≥2 
episodes of acute complications (coma, ketoacidosis), 1 episode of an 
acute complication, and late complications only.
Identification of Gestational Diabetes Mellitus
In women without pregestational diabetes mellitus, we identified 
women who developed gestational diabetes mellitus (ICD-8 code 
634.74; ICD-10 code O24.4) in the second trimester (13–27 gesta-
tional weeks) or third trimester (≥28 gestational weeks).
Identification and Classification of Offspring CHDs
We identified persons with CHDs (ICD-8 codes 740–759, ICD-10 
codes Q20–Q26) by using the NPR and the Causes of Death Register. 
CHDs were classified by using a previously published algorithm 
that uses a hierarchical approach to map CHDs into embryologically 
related defect phenotypes.13,21,22 These phenotypes were heterotaxia, 
conotruncal defect (truncus arteriosus, transposition of the great 
arteries, Tetralogy of Fallot, double-outlet right ventricle, other), 
atrioventricular septum defect, anomalous pulmonary venous return, 
left ventricular outflow tract obstruction (coarctation of the aorta, val-
vular aortic stenosis, other), right ventricular outflow tract obstruction 
(valvular pulmonary stenosis, other), atrial septum defect, ventricular 
septum defect, complex defect, valve defect, other specified defect, 
and unspecified defect. Isolated physiological heart conditions (per-
sistent foramen ovale, pulmonary valve stenosis) present at birth but 
not mentioned at >6 weeks postnatal age, and persistent ductus arte-
riosus were not considered CHDs. ICD codes for severe CHDs have 
been validated against hospital records with very good agreement.23 
In preliminary analyses, we distinguished between individuals with 
isolated CHDs and CHDs with extracardiac birth defects (ICD-10 
codes Q00–Q19, Q27–Q99). Individuals with CHD and 1 minor 
defect24 were considered to have isolated CHD.
Identification of Offspring Noncardiac Birth Defects
Using the NPR, we also identified all individuals born in the period 
1994 to 2011 with noncardiac birth defects (ICD-10 codes Q00–Q19, 
Q27–Q99). Individuals with isolated minor defects24 were not consid-
ered to have birth defects.
Statistical Analysis
Associations between maternal diabetes mellitus and offspring risk 
of CHD were estimated as risk ratios (RRs) with 95% confidence 
intervals (CIs) using log-linear binominal regression, with adjust-
ment for year of delivery (1-year groups), maternal age in years (<20, 
20–24, 25–29, 30–34, 35–39, ≥40), and birth order (first, second, or 
later; PROC GENMOD, SAS Institute, Inc., Cary, NC). Polytomous 
logistic regression (PROC NLMIXED in SAS) was used to test for 
differences between multiple outcomes. We addressed 2 specific 
hypotheses whether the effects of diabetes mellitus differ across sec-
tions of the embryonic heart corresponding to specific cardiac phe-
notypes,5–9 by testing whether the RRs were similar for the different 
outcomes of conotruncal versus nonconotruncal defects, and cardiac 
defects originating from the anterior secondary heart field versus 
those defects from the posterior heart field. All tests were likelihood 
ratio tests. In trend tests, the number of complications were entered 
as continuous variables. Analyses restricting to a woman’s first birth 
revealed that the potential correlation between sibling outcomes did 
not affect the observed RRs and CIs; consequently, we present results 
based on all offspring. Assuming a causal relationship between 
maternal pregestational diabetes mellitus and infant CHD, we calcu-
lated the attributable fraction among the exposed as (adjusted RR–1/
adjusted RR)×100,25 interpreted as the proportion of CHDs among 
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the offspring of diabetic mothers that could be attributed to maternal 
diabetes mellitus.
Medications used to treat diabetes mellitus might potentially have 
teratogenic effects. Therefore, we estimated RRs for CHD in the off-
spring of diabetic mothers by maternal use of antidiabetic medications 
(insulin, oral antidiabetic medications, oral antidiabetic medications 
and insulin, no antidiabetic treatment) between 14 and 56 days ges-
tation, the presumed window of susceptibility for embryonic heart 
development. Antidiabetic medication use was determined by using 
information from the Register of Medicinal Product Statistics on dates 
relevant prescriptions were filled and the amount of medication dis-
pensed, and the World Health Organization’s Defined Daily Dose.26
To evaluate whether there are unknown common factors for 
maternal diabetes mellitus and CHD, we also compared the postges-
tational risk of diabetes mellitus in women with and without offspring 
with CHDs. In this analysis, the study cohort included women with 
≥1 births between 1994 and 2011, excluding mothers with diabetes 
mellitus before their first birth. We followed the women from their 
first birth after 1994 until diabetes mellitus (outcome), death, emi-
gration, or end of follow-up (December 2011). The relative risk of 
diabetes mellitus after a CHD birth was estimated by rate ratios using 
log-linear Poisson regression, with history of CHD birth as a time-
dependent variable and adjustment for maternal age at birth, birth 
order, and year of delivery.
Approvals
Statens Serum Institut has approval from the Danish Data Protection 
Agency to conduct register-based studies. The Danish Cytogenetic 
Central Register Board approved the study.
Results
There were 2 043 548 living singletons born in Denmark in 
the period 1978 to 2011. Of these, 6595 had a chromosomal 
aberration, 4942 had syndromic CHD, and 6750 had a mother 
with a CHD. These 17 821 persons were therefore excluded 
from the study population, leaving 2 025 727 (1 077 836 moth-
ers) in the study cohort (Table 1). The proportion of offspring 
exposed to maternal pregestational diabetes mellitus was 
0.36% (n=7296); this proportion increased with year of birth, 
increasing maternal age, and number of births. The overall 
prevalence of nonchromosomal CHDs was 81 per 10 000 
births (n=16 325).
Offspring of women with pregestational diabetes mellitus 
were 4 times more likely to have CHDs than the offspring of 
mothers without diabetes mellitus (Table 2); (prevalence of 
Table 1. Prevalence of Maternal Pregestational Diabetes Mellitus* and CHDs† by Birth Characteristics in 2 025 727 
Singleton Births,‡ Denmark, 1978 to 2011
Birth Characteristics All Births‡
Births‡ with  
Pregestational Diabetes Mellitus* Births‡ with CHDs†
n (%) Prevalence per 1000 n (%)
Prevalence per 
10 000
Total 2 025 727 7296 3.6 16 325 81
Year of infant birth
  1978–1986 480 868 (23.7) 1107 (15.2) 2.3 3397 (20.8) 71
  1987–1993 424 020 (20.9) 1516 (20.8) 3.6 3461 (21.2) 82
  1994–2011 1 120 839 (55.3) 4673 (64.0) 4.2 9467 (58.0) 84
Maternal age at birth
  0–19 51 886 (2.6) 91 (1.3) 1.8 461 (2.8) 89
  20–24 380 525 (18.8) 1043 (14.3) 2.7 3233 (19.8) 85
  25–29 752 817 (37.2) 2490 (34.1) 3.3 5938 (36.4) 79
  30–34 589 912 (29.1) 2292 (31.4) 3.9 4602 (28.2) 78
  35–39 216 160 (10.7) 1103 (15.1) 5.1 1778 (10.9) 82
  40+ 34 427 (1.7) 277 (3.8) 8.0 313 (1.9) 91
Birth order
  First 901 271 (44.5) 2901 (39.8) 3.2 7414 (45.4) 82
  Second 753 302 (37.2) 2842 (38.9) 3.8 5730 (35.1) 76
  Third or more 371 154 (18.3) 1553 (21.3) 4.2 3181 (19.5) 86
Infant sex
  Male 1 040 002 (51.3) 3722 (51.0) 3.6 8525 (52.2) 82
  Female 985 705 (48.7) 3574 (49.0) 3.6 7800 (47.8) 79
CHD indicates congenital heart defects; ICD-8, International Classification of Diseases, 8th Revision; and ICD-10, International Classification of 
Diseases, 10th Revision.
*Pregestational diabetes mellitus defined as first-time diagnosis in the National Patient Register; ICD-8 codes, 250 (1977–1986), 249, 250 (1987–
1993); ICD-10 codes, E10, E11 (1994–2011).
†CHDs: ICD-8 codes, 740–759; ICD-10 codes, Q20–Q26, not counting isolated physiological heart conditions (persistent foramen ovale, persistent 
ductus arteriosus, and pulmonary valve stenosis).
‡Singletons births after excluding 17 821 births (6750 maternal CHD, 6595 chromosomal aberrations, and 4942 syndromes).
 by guest on M
ay 4, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
2246  Circulation  June 7, 2016
Table 2. Relative Risk of Any Type of CHD,* Overall, and by Diagnosis Characteristics of Pregestational Diabetes Mellitus,† 
Pregestational Diabetes Complications, and Birth Characteristics in 2 025 727 Live Births,‡ Denmark, 1978 to 2011
Characteristics
Live Births‡ With 
Pregestational  
Diabetes Mellitus†  
n (%)
CHD* in Births With 
Pregestational Diabetes Mellitus
RR Crude (95% CI)
RR Adjusted§  
(95% CI) P Value‖n
Prevalence per 
10 000
Overall¶ 7296 232 318 3.99 (3.50–4.52) 4.00 (3.51–4.53) <0.0001
Diagnosis characteristics
  Maternal age at diagnosis, y
   <30 6297 (86.3) 202 321 4.02 (3.50–4.60) 4.03 (3.50–4.60) 0.76
   ≥30 999 (13.7) 30 300 3.77 (2.59–5.25) 3.80 (2.61–5.30)
  Period of maternal diagnosis
   1977–1993 5152 (70.6) 158 307 3.85 (3.28–4.47) 3.80 (3.24–4.41) 0.22
   1994–2011 2144 (29.4) 74 345 4.33 (3.43–5.37) 4.51 (3.57–5.60)
  Period and age of maternal diagnosis
   1977–1993
    <30 y 4779 (92.8) 150 314 3.94 (3.36–4.61) 3.88 (3.30–4.52) 0.44
    ≥30 y 373 (7.2) 8 214 2.69 (1.36–5.34) 2.71 (1.25–5.00)
   1994–2011
    <30 y 1518 (70.8) 52 343 4.30 (3.29–5.61) 4.52 (3.41–5.84) 0.20
    ≥30 y 626 (29.2) 22 351 4.39 (2.91–6.62) 4.52 (2.90–6.64)
  Time since diabetes diagnosis
   <1 y 168 (2.3) 6 357 4.34 (1.74–8.64) 4.27 (1.72–8.52) 0.93
   1–5 y 2923 (39.9) 94 322 3.91 (3.18–4.74) 4.03 (3.27–4.88)
   ≥6 y 4230 (57.8) 137 324 3.94 (3.32–4.62) 3.86 (3.26–4.54)
Complications, pregestational#
  No complications 4429 (60.7) 123 278 3.48 (2.91–4.13) 3.49 (2.91–4.13) 0.02
  Any complication 2867 (39.3) 109 380 4.77 (3.94–5.70) 4.78 (3.95–5.72)
  Type of complications
   No complications 4429 (60.7) 123 278 3.48 (2.91–4.13) 3.49 (2.91–4.13)
   One acute complication 466 (6.4) 29 622 7.81 (5.35–10.9) 7.62 (5.23–10.6) 0.0004**
    Coma 341 (4.7) 22 645 8.09 (5.22–11.7) 7.79 (5.03–11.3)
    Ketoacidosis 125 (1.7) 7 560 7.02 (3.07–13.2) 7.13 (3.11–13.4)
   One late complication 1157 (15.9) 35 310 3.79 (2.68–5.17) 3.84 (2.71–5.23) 0.61**
    Retinopathy 736 (10.1) 21 285 3.58 (2.27–5.30) 3.68 (2.33–5.45)
    Nephropathy 26 (0.36) 0 - -
    Neuropathy 34 (0.47) 1 294 3.69 (0.21–15.5) 3.50 (0.20–14.6)
    Vasculopathy 22 (0.30) 0 - -
    Any other 1 complication 339 (4.6) 13 383 4.81 (2.67–7.82) 4.76 (2.64–7.74)
   ≥2 complications 1244 (17.0) 45 362 4.54 (3.35–5.96) 4.56 (3.37–5.99) 0.13**
  Number of complications
   No complications 4429 (60.7) 123 278 3.48 (2.91–4.13) 3.49 (2.91–4.13)
   Any late complication only 1750 (24.0) 53 303 3.80 (2.88–4.90) 3.85 (2.91–4.96)
   One acute complication±late 1020 (14.0) 50 490 6.15 (4.62–7.96) 6.06 (4.56–7.85)
   ≥2 acute complications±late 97 (1.3) 6 619 7.76 (3.14–15.2) 7.83 (3.17–15.3) 0.008††
(Continued )
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CHD at birth 318 per 10 000 versus 80 per 10 000). RR mag-
nitudes did not depend on maternal age at onset of diabetes 
mellitus or duration of diabetes mellitus. Before 1994, 92.8% 
of diabetic mothers were diagnosed before 30 years of age, 
whereas only 70.8% had an early diagnosis thereafter, but RR 
magnitudes did not depend on maternal age at diabetes onset 
in either period. Among the offspring of diabetic mothers, the 
proportions of CHDs attributable to maternal diabetes mel-
litus in 1978 to 1986, 1987 to 1993, and 1994 to 2011, were 
79%, 76%, and 74%, respectively.
Among women with pregestational diabetes mellitus, 
39.3% had pregestational diabetic complications. Offspring 
of women with single acute pregestational complications 
had a significantly higher CHD risk than the offspring of 
women without diabetes complications (P=0.0004), whereas 
the risk in offspring of women with single late complications 
was similar to that of the offspring of women without com-
plications (P=0.61, Table 2). Using an alternative approach 
(dose-response), ≥2 episodes of acute complications (coma, 
ketoacidosis), 1 acute complication episode, and late compli-
cations only, the RRs were 7.83, 6.06, and 3.85, respectively, 
P(trend)=0.008.
Information on initial antidiabetic treatment (a proxy for 
diabetes type) was available for women delivering from 1996 
to 2011. RRs for CHD did not differ by type of treatment 
(insulin versus oral antidiabetic medications/no antidiabetic 
treatment (P=0.56, Table 3).
Maternal pregestational diabetes mellitus was associated 
with increased risks of most CHD phenotypes, with RRs 
ranging from 2.74 to 13.8 (Table 4). In 2 analyses chosen 
Birth characteristics
  Year of infant birth
   1978–1986 1107 (15.2) 36 325 4.64 (3.30–6.30) 4.66 (3.31–6.33) 0.55
   1987–1993 1516 (20.8) 50 330 4.09 (3.06–5.31) 4.11 (3.08–5.34)
   1994–2011 4673 (64.0) 146 312 3.74 (3.17–4.38) 3.82 (3.24–4.47)
  Maternal age at birth, y
   0–24 1134 (15.5) 38 335 3.95 (2.84–5.32) 3.94 (2.82–5.30) 0.10
   25–29 2490 (34.1) 84 337 4.32 (3.47–5.30) 4.30 (3.45–5.27)
   30–34 2292 (31.4) 63 275 3.56 (2.75–3.50) 3.58 (2.77–4.53)
   35+ 1380 (18.9) 47 341 4.15 (3.08–5.44) 4.17 (3.10–5.47)
  Birth order
   1 2901 (39.8) 89 307 3.76 (3.04–4.59) 3.72 (3.01–4.54) 0.77
   2 2842 (38.9) 88 310 4.12 (3.32–5.03) 4.13 (3.33–5.04)
   ≥3 1553 (21.3) 55 354 4.19 (3.18–5.38) 4.23 (3.21–5.43)
  Infant sex
   Male 3722 (51.0) 102 274 3.37 (2.76–4.06) 3.37 (2.76–4.06) 0.01
   Female 3574 (49.0) 130 364 4.66 (3.91–5.49) 4.67 (3.92–5.52)
CHD indicates congenital heart defects; CI, confidence interval; df, degree of freedom; ICD-8, International Classification of Diseases, 8th Revision; ICD-10, 
International Classification of Diseases, 10th Revision; and RR, relative risk.
*CHDs: ICD-8 codes, 740–759 (1978–1993); ICD-10 codes, Q20–Q26 (1994–2011), not counting isolated physiological conditions (persistent foramen ovale, 
persistent ductus arteriosus, and pulmonary valve stenosis).
†Pregestational diabetes mellitus defined as first-time diagnosis in the National Patient Register; ICD-8 codes, 250 (1977–1986), 249, 250 (1987–1993); ICD-10 
codes, E10, E11 (1994–2011).
‡Singletons births after excluding 17 821 births (6750 maternal CHD, 6595 chromosomal aberrations, and 4942 syndromes).
§RRs with 95% CIs adjusted for infant year of birth (each year), maternal age (0–19, 20–29, 30–39, 40+), and birth order (1, ≥2), comparing CHD risk in births with 
pregestational diabetes mellitus and CHD risk in births without pregestational diabetes mellitus (reference).
‖P value comparing exposed/unexposed, levels of diagnosis characteristics or complications, and effect modifiers (birth characteristics).
¶CHD birth prevalence without pregestational diabetes mellitus (reference); 80 per 10 000 [(16 093/2 018 431)×10 000].
#Pregestational diabetes complications, 1 acute (coma [E10.0, E11.0, 249.06, 249.07, 250.06, 250.07]; ketoacidosis [E10.1, E11.1]), 1 late (nephropathy [E10.2, 
E11.2, 249.02, 250.02]; retinopathy [E10.3, E11.3, 249.01, 250.01, H36]; neuropathy [E10.4, E11.4, 249.03, 250.03]; vasculopathy/angiopathy [E10.5, E11.5, 249.04, 
249.05, 250.04, 250.05]; or any other 1 complication [E10.6, E11.6, E10.8, E11.8, 249.08, 250.08]), and ≥2 complications (multiple complications [E10.7, E11.7], or 
≥2 of the above complications).
**Comparing no complication with 1 acute complication (χ2=12.64, 1 df), with 1 late complication (χ2=0.25, 1 df), and with ≥2 complications (χ2=2.32, 1 df).
††Trend test (χ2=7.09, 1 df).
Table 2. Continued
Characteristics
Live Births‡ With 
Pregestational  
Diabetes Mellitus† 
n (%)
CHD* in Births With 
Pregestational Diabetes Mellitus
RR Crude (95% CI)
RR Adjusted§  
(95% CI) P Value‖n
Prevalence per 
10 000
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specifically, the RRs for conotruncal defects (RR, 5.44) 
and nonconotruncal defects (atrioventricular septal defects, 
anomalous pulmonary venous return, left or right ventricular 
outflow tract obstructions, ventricular septum defect, atrial 
septum defect, ventricular septum defect + atrial septum 
defect, isolated valve defects, other specified; RR, 3.78; 95% 
CI, 3.22–4.39) were significantly different from one another 
(P=0.05). Furthermore, the RR of cardiac defects originating 
from the anterior secondary heart field (truncus arteriosus, 
Tetralogy of Fallot, double-outlet right ventricle, left ven-
tricular outflow tract obstruction, ventricular septum defect; 
RR, 4.31; 95% CI, 3.54–5.17) was significantly different from 
those defects from the posterior secondary heart field (anoma-
lous pulmonary venous return, atrial septum defect; RR, 2.84; 
95% CI, 1.84–4.13), the P value was 0.04.
Pregestational Diabetes Mellitus and Offspring Risk 
of Noncardiac Birth Defects
Among 1 120 839 singletons born in 1994 to 2011, 4673 
(0.42%) were born to women with pregestational diabetes 
mellitus and 28 780 (25.7 per 1000 births) had noncardiac 
birth defects. The risk of noncardiac birth defects was 66% 
greater in the offspring of women with pregestational dia-
betes mellitus than in the offspring of nondiabetic women 
(RR, 1.66; 95% CI, 1.44–1.90; n=195); this RR differed sig-
nificantly (P<0.0001) from the corresponding RR for cardiac 
birth defects (RR, 3.82; 95% CI, 3.24–4.47).
Gestational Diabetes Mellitus and Offspring  
Risk of CHD
Among 2 018 431 singleton pregnancies without pregesta-
tional diabetes mellitus, gestational diabetes mellitus was 
diagnosed in the second or third trimester for 5685 and 6716 
pregnancies, respectively (Table 5). RRs for offspring CHD 
were RRs 1.26; 95% CI, 0.95 to 1.62 and 1.36; 95% CI, 1.07 
to 1.69, for gestational diabetes mellitus in the second and 
third trimesters, respectively. These RRs differed significantly 
(P=0.007) from the RR for CHD in offspring of women with 
pregestational diabetes mellitus.
Maternal Antidiabetic Medication Use in Gestational 
Weeks 2 to 8 and Offspring Risk of CHD
Information on antidiabetic treatment in very early pregnancy 
was available for women delivering between 1996 and 2011. 
RRs for CHD did not differ by type of treatment (P=0.95, 
Table 6).
Offspring CHD and Risk of Subsequent Maternal 
Diabetes Mellitus
Among 1 110 363 women with ≥1 births since 1977, 9219 
had a child with CHD, and 17 888 developed diabetes mel-
litus after delivery; 321 (3.5%) women both had a child with 
a CHD and developed diabetes mellitus. The RR for later dia-
betes mellitus associated with CHD in the offspring was 1.42 
(95% CI, 1.27–1.59).
Sensitivity Analysis; Potential Selection Bias 
Attributable to Pregnancy Termination
In the period 1994 to 2011, 1 120 839 live singletons were born, 
including 4673 (0.4%) born to women with pregestational dia-
betes mellitus. CHDs were identified in 146 (3.1%) children 
born to diabetic women and 9321 (0.8%) children born to non-
diabetic women; the unadjusted RR was 3.74 (Table 2). In the 
same period, 3075 pregnancies, including 38 (1.2%) in diabetic 
women, were terminated because of fetal disease. In 2 extreme 
scenarios (including live births and terminated pregnancies), all 
38 fetuses exposed to pregestational diabetes mellitus, and none 
of the 3037 unexposed fetuses, had CHD, yielding an unad-
justed RR of 4.7; or none of the 38 exposed fetuses and all 3037 
unexposed fetuses had CHD, yielding an unadjusted RR of 2.8.
Table 3. Relative Risk of Any Type of CHD* by Information of Pregestational Diabetes Mellitus,† and Pregestational 
First-Time Prescription‡ of Insulin or Noninsulin Treatment, in 466 076 Singleton Live Births,§ Denmark, 1996 to 2011
Pregestational 
Diabetes Mellitus†
First-Time 
Pregestational 
Treatment‡
Births§ 
N=466 076 
n (%)
CHD* n=3625
RR Crude  
(95% CI)
Adjusted RRǁ,¶ 
(95% CI)No.
Prevalence per 
10 000
Yes Total 1905 (0.41) 55 289 3.75 (2.85–4.83) 3.88 (2.95–4.99)
Insulin 1497 (0.32) 42 281 3.65 (2.66–4.85) 3.73 (2.72–4.96)
Non-insulin 408 (0.09) 13 319 4.14 (2.29–6.76) 4.47 (2.47–7.28)
No 464 171 3570 77 1 (reference) 1 (reference)
ATC indicates Anatomic Therapeutic Chemical; CHD, congenital heart defects; CI, confidence interval; df, degree of freedom; ICD-8, International 
Classification of Diseases, 8th Revision; ICD-10, International Classification of Diseases, 10th Revision; and RR, relative risk.
*CHDs: ICD-10 codes, Q20–Q26, not counting isolated physiological conditions (persistent foramen ovale, persistent ductus arteriosus, and pulmonary 
valve stenosis).
†Pregestational diabetes mellitus defined as first-time diagnosis in the National Patient Register; ICD-8 codes, 250 (1977–1986), 249, 250 (1987–
1993); ICD-10 codes, E10, E11 (1994–2011).
‡Insulin (ATC Classification system code A10A) and noninsulin (ie, oral antidiabetic medications; ATC code A10B), or no medication, in the Register of 
Medicinal Product Statistics, 1996–2011.
§Singleton births, 1996–2011 in mothers born 1974 onward, after excluding 4422 births (2377 maternal CHD, 1245 chromosomal aberrations, and 
800 syndromes).
ǁRRs with 95% CIs adjusted for year of birth (each year), maternal age at birth (0–19, 20–24, 25–29, 30–34, 35+), and birth order (1, ≥2) comparing 
CHD risk in births with pregestational diabetes mellitus and CHD risk in births without pregestational diabetes mellitus (reference).
¶Test comparing insulin vs noninsulin, χ2=0.33, P=0.56.
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Discussion
In this study of 2 million births over a 34-year period, the larg-
est of its kind to date, maternal pregestational diabetes mel-
litus was associated with a 4-fold increase in offspring CHD 
risk. The increase in CHD risk was stable over time, and was 
similar for type 1 and type 2 diabetes mellitus. Pregestational 
acute diabetic complications conferred an almost 8-fold 
increase in CHD risk in comparison with nondiabetic women. 
Maternal pregestational diabetes mellitus was associated with 
an increased risk of all CHD subtypes, with a higher risk for 
Table 4. Birth Prevalence and Relative Risk of Type-Specific CHDs by Pregestational Diabetes in 2 025 727 Live 
Births, Denmark, 1978 to 2011
Cardiac Phenotype
All Births
N=2 025 727  
n (per 10 000)
Births with Pregestational 
Diabetes Mellitus
n=7296 n (per 10 000) RR Crude (95% CI) RR Adjusted* (95% CI)
Any type CHD 16 325 (80.6) 232 (318) 3.99 (3.50–4.52) 3.96 (3.48–4.49)
Heterotaxia 198 (0.98) 6 (8.22) 8.65 (3.41–17.8) 8.76 (5.16–13.8)
Conotruncal defects 1626 (8.03) 32 (43.9) 5.55 (3.84–7.73) 5.44 (3.76–7.58)
  Truncus arteriosus† 142 (0.70) 7 (9.59) 14.3 (6.08–28.4) 13.8 (5.82–27.3)
  TGA 665 (3.28) 10 (13.1) 4.22 (2.11–7.45) 4.20 (2.10–7.41)
  ToF 611 (3.02) 8 (11.0) 3.67 (1.67–6.87) 3.65 (1.66–6.84)
  DORV 95 (0.47) 4 (5.48) 12.2 (3.72–29.1) 11.3 (9.05–14.0)
  Other conotruncal‡ 113 (0.56) 3 (4.11) 7.54 (1.86–20.0) 6.75 (1.66–17.9)
AVSD 485 (2.39) 9 (12.3) 5.23 (2.50–9.50) 5.27 (2.52–9.57)
APVR 142 (0.70) 2 (2.74) 3.95 (0.65–12.4) 3.63 (0.60–11.4)
LVOTO 1524 (7.52) 15 (20.6) 2.75 (1.58–4.40) 2.74 (1.57–4.38)
  CoA 783 (3.87) 8 (11.0) 2.86 (1.30–5.34) 2.87 (1.31–5.36)
  Valvular aortic stenosis 487 (2.40) 6 (8.22) 3.45 (1.37–7.03) 3.45 (1.37–7.04)
  Other LVOTO§ 254 (1.25) 1 (1.37) 1.09 (0.06–4.85) 1.05 (0.06–4.65)
RVOTO 1000 (4.94) 15 (20.6) 4.21 (2.42–6.75) 4.01 (2.30–4.42)
  vPS 802 (3.96) 13 (17.8) 4.56 (2.50–7.54) 4.38 (2.40–7.25)
  Other RVOTO‖ 198 (0.98) 2 (2.74) 2.82 (0.48–8.81) 2.58 (0.43–8.06)
Septal defects 7092 (35.0) 102 (140) 4.04 (3.30–4.87) 3.92 (3.21–4.73)
  VSD 4523 (22.3) 73 (100) 4.54 (3.57–5.66) 4.43 (3.49–5.54)
  ASD 2127 (10.5) 22 (30.2) 2.89 (1.84–4.28) 2.79 (1.78–4.14)
  VSD+ASD 342 (1.69) 7 (9.59) 5.78 (2.45–11.3) 5.32 (2.73–10.4)
  Unspecified 100 (0.49) 0 – –
Complex¶ 33 (0.16) 0 – –
Valve defects# 692 (3.42) 7 (9.59) 2.83 (1.21–5.49) 2.91 (1.25–5.66)
Other specified 881 (4.35) 10 (13.7) 3.18 (1.59–5.92) 3.45 (1.73–6.08)
Unspecified 2652 (13.1) 34 (46.6) 3.59 (2.51–4.95) 3.75 (2.63–5.17)
APVR indicates anomalous pulmonary venous return; ASD, atrial septal defect; AVSD, atrioventricular septal defect; CHD, congenital heart defects; 
CI, confidence interval; CoA, coarctation of aorta; DORV, double outlet of the right ventricle; LVOTO, left ventricular outflow tract obstructions; RR, 
relative risk; RVOTO, right ventricular outflow tract obstructions; TGA, transposition of the great arteries; ToF, Tetralogy of Fallot; vPS, valvular 
pulmonary stenosis; and VSD, ventricular septal defect.
*RR with 95% CI adjusted for birth year (1978–1993, 1994–2011), maternal age (<20, 20–29, 30–39, 40+), and birth order (1, ≥2) comparing 
CHD risk in births with pregestational diabetes mellitus and CHD risk in births without pregestational diabetes mellitus (reference). Adjusted RR for 
any type CHD was slightly different from Table 2 because of adjustment variables with fewer categories.
†Truncus arteriosus, including aorta-pulmonary window (1 exposed case).
‡Aortic arterial atresia/stenosis/hypoplasia.
§Hypoplastic left heart syndrome (1 exposed), mitral stenosis/atresia (0 exposed).
‖Hypoplastic right heart syndrome (0 exposed), Ebstein anomaly (1 exposed), pulmonary valve atresia (1 exposed), and pulmonary artery atresia 
(0 exposed).
¶Single ventricle, congenital corrected TGA.
#Isolated valve defects not included in LVOTO or RVOTO.
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cardiac outflow defects. Cardiac defects were significantly 
more prevalent than noncardiac defects among the offspring 
of diabetic women.
Our finding of the 4-fold increased CHD risk in offspring 
of mothers with pregestational diabetes mellitus, in comparison 
with offspring of nondiabetic mothers, is consistent with 3 pub-
lished population-based studies of CHD risk in diabetic women 
(ie, in the United States,11 in Norway,3 and lately, in Canada13).
In recent years, prenatal care has improved and aware-
ness of optimal glucose regulation before pregnancy has 
increased.27 However, our study results suggest that this 
improved care has not diminished the risk of offspring 
CHD for diabetic mothers. Indeed, the CHD risk associated 
with maternal diabetes mellitus changed very little over 34 
years, and, among offspring born to diabetic mothers, 75% 
of CHD cases could be attributed to maternal diabetes mel-
litus. Other variables that changed over the study period 
(eg, increasing prevalence of obesity and type 2 diabetes 
mellitus, increasing maternal age) may have outweighed 
the effects of better prenatal care at the population level. 
Alternatively, pregestational diabetes mellitus may be asso-
ciated with adverse fetal cardiac development independent 
Table 6. Relative risk of any type of CHD* by Information of Pregestational Diabetes Mellitus† and Antidiabetic Medication‡ in 
Gestational Weeks 2 through 8, in 987 576 Singleton Live Births,§ Denmark, 1996 to 2011
Pregestational 
Diabetes Mellitus†
Antidiabetic 
Treatment‡ Covering 
Gestational Weeks 2–8
Births§  
N=987 576 
n (%)
CHD* n=8146
RR Crude (95% CI)
Adjusted RRǁ,¶ 
(95% CI)n
Prevalence per 
10 000
Yes Insulin 2845 (0.29) 87 306 3.75 (3.02–4.59) 3.83 (3.08–4.68)
Tablets/insulin 104 (0.01) 4 385 4.72 (1.58–10.7) 5.14 (1.62–11.6)
Tablets 181 (0.02) 5 276 3.39 (1.23–7.17) 3.59 (1.30–7.59)
No medication 1071 (0.11) 33 308 3.78 (2.64–5.19) 3.83 (2.68–5.26)
No 983 375 8017 82 1 (reference) 1 (reference)
ATC indicates Anatomic Therapeutic Chemical; CHD, congenital heart defects; CI, confidence interval; df, degree of freedom; ICD-8, International Classification 
of Diseases, 8th Revision; ICD-10, International Classification of Diseases, 10th Revision; and RR, relative risk.
*CHDs: ICD-10 codes, Q20–Q26, not counting isolated physiological conditions (persistent foramen ovale, persistent ductus arteriosus, and pulmonary valve 
stenosis).
†Pregestational diabetes mellitus defined as first-time diagnosis in the National Patient Register; ICD-8 codes, 250 (1977–1986), 249, 250 (1987–1993); ICD-10 
codes, E10, E11 (1994–2011).
‡Insulin (ATC Classification system code A10A), tablets (ie, oral antidiabetic medications; ATC code A10B), or no medication, in the Register of Medicinal Product 
Statistics, 1996–2011.
§Singleton births, 1996–2011, after excluding 9184 births (4093 maternal CHD, 3020 chromosomal aberrations, and 2362 syndromes).
ǁRRs with 95% CIs adjusted for delivery year (each year), maternal age at delivery (0–19, 20–24, 25–29, 30–34, 35–39, 40+), and birth order (1, 2, ≥3) 
comparing CHD risk in births with pregestational diabetes mellitus and CHD risk in births without pregestational diabetes mellitus (reference). 
¶Test for homogeneity, treatments insulin, tablet/insulin, tablets, and no medication, χ2=0.35, 3 df, P=0.95.
Table 5. Relative Risk of Any Type of CHD* by Information of Pregestational Diabetes Mellitus,† Gestational Diabetes 
Mellitus (Second Trimester, Third Trimester),‡ in 2 025 727 Singleton Live Births,§ Denmark, 1978 to 2011
Maternal Diabetes Mellitus
Births§
N=2 025 727
n
CHD* n=16 325
RR Crude (95% CI) Adjusted RRǁ (95% CI)n
Prevalence 
per 10 000
Pregestational diabetes mellitus† 7296 232 318 4.00 (3.51–4.53) 4.01 (3.52–4.54)
Gestational diabetes mellitus, second trimester‡ 5685 55 97 1.22 (0.92–1.56) 1.26 (0.95–1.62)
Gestational diabetes mellitus, third trimester‡ 6716 74 110 1.38 (1.09–1.72) 1.36 (1.07–1.69)
No diabetes mellitus 2 006 030 15 964 80 1 (reference) 1 (reference)
CHD indicates congenital heart defects; CI, confidence interval; ICD-8, International Classification of Diseases, 8th Revision; ICD-10, International Classification 
of Diseases, 10th Revision; and RR, relative risk.
*CHDs: ICD-10 codes, Q20–Q26, not counting isolated physiological conditions (persistent foramen ovale, persistent ductus arteriosus, and pulmonary valve 
stenosis).
†Pregestational diabetes mellitus defined as first-time diagnosis in the National Patient Register, ICD-8 codes, 250 (1977–1986), 249, 250 (1987–1993); 
ICD-10 codes, E10, E11 (1994–2011).
‡Gestational diabetes mellitus in current pregnancy, registered in the National Patient Register, ICD-8 code, 634.74 (1977–1993); ICD-10 code, O24.4 
(1994–2011), in second trimester (13–27 gestational weeks) and third trimester (≥28 gestational weeks), and without pregestational diabetes mellitus.
§Singletons births after excluding 17 821 births (6750 maternal CHD, 6595 chromosomal aberrations, and 4942 syndromes).
ǁRRs with 95% CIs adjusted for delivery year (each year), maternal age at delivery (0–19, 20–24, 25–29, 30–34, 35–39, 40+), and birth order (1, 2, ≥3) 
comparing CHD risk in births with maternal diabetes mellitus and CHD risk in births without maternal diabetes mellitus (reference).
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of prenatal care, changing risk factors, and diabetes type. In 
our study, offspring CHD risk was not modified by timing 
of disease onset or duration of maternal diabetes mellitus.
The offspring of women whose initial pregestational 
diabetes treatment was insulin (most likely type 1 dia-
betes mellitus) had the same CHD risk as the offspring 
of women first treated with oral antidiabetic medications 
or no medication (most likely type 2 diabetes mellitus). 
Similar birth defect and CHD risks have been reported for 
type 1 and 2 diabetes mellitus in other studies.1,13 Because 
type 1 and type 2 diabetes mellitus have different etiolo-
gies, these results suggest that fetal heart development 
is susceptible to pathological processes shared by both 
diabetes types (eg, high glucose levels, reduced insulin 
sensitivity/increased insulin resistance, changes in triglyc-
erides, oxidative stress, and inflammation). Interestingly, 
gestational diabetes mellitus was only weakly associated 
with offspring CHD risk, implying that high glucose lev-
els very early in pregnancy may be key to abnormal heart 
development.5–9
The prevailing hypothesis explaining the observed associa-
tion between maternal diabetes mellitus and offspring CHD is 
that excess glucose exerts a teratogenic effect on the develop-
ing heart.28 However, glucose itself is not a mutagen; instead, 
it may exert a teratogenic effect via a signaling pathway regu-
lating insulin sensitivity. Insulin sensitivity is thought to be 
involved in the pathophysiology of both type 1 and type 2 
diabetes mellitus,29 and insulin and related signaling pathways 
are also key mediators of embryogenesis and early develop-
ment.29,30 Glucose may also affect gene expression in embry-
onic development via epigenetic changes (histone acetylation, 
microRNA expression).31 The alternative, that offspring CHD 
reflects maternally inherited genetic or epigenetic variations 
that confer risk of both diabetes mellitus and cardiac abnor-
malities, is less likely, because the risk of maternal diabetes 
mellitus subsequent to birth of a child with CHD was only 
modestly increased.
We did not have information on maternal pregesta-
tional glucose levels. However, we investigated offspring 
CHD risk by number and type of maternal diabetic com-
plications (a proxy for the degree to which maternal glu-
cose levels were uncontrolled). Almost 40% of women 
with pregestational diabetes mellitus had experienced 
diabetic complications, but only women with acute com-
plications or multiple complications had higher offspring 
CHD risks than women with no diabetic complications. 
A recent British study also reported higher risks of con-
genital anomalies in offspring of diabetic mothers with 
high pregestational glucose levels or other clinical corre-
lates of hyperglycemia.12 However, this study also found 
an increased risk of congenital anomalies associated with 
late diabetic complications.12 The lack of excess CHD 
risk associated with single late complications in our study 
could be related to coding practices; serious late compli-
cations may have been coded as multiple complications 
or unspecified. Because the degree of insulin sensitivity 
is highly correlated with diabetic complications,32 these 
findings support the hypothesis that insulin sensitivity may 
be mechanistically involved in the association between 
CHD and pregestational diabetes mellitus.
Conotruncal defect risk increased in the offspring of dia-
betic women, consistent with experimental study findings 
that hyperglycemia in early pregnancy affects regulatory 
gene expression in the embryo, leading to cardiac neural 
crest cell death and increased CHD risk, particularly for 
conotruncal and outflow tract abnormalities.5–7 When we 
grouped the outflow tract malformations and the inflow tract 
malformations to correspond to the anterior and posterior 
second heart fields in early embryonic development,8,9 we 
found that the association with maternal diabetes mellitus 
was much stronger for anterior second heart field defects 
than posterior second heart field defects, suggesting that the 
most sensitive cell populations are located in the anterior 
second heart field.8 However, more detailed mechanistic 
studies will be required to define the role of glucose sensi-
tivity in cells from the neural crest and anterior second heart 
field during cardiac development. Maternal diabetes mel-
litus was also associated with the entire spectrum of CHD 
phenotypes. The nonspecific nature of the association sug-
gests that hyperglycemia in early pregnancy may not only 
influence specific sequences in cardiac development, but 
affects cardiac development in general, or exerts its detri-
mental effect before formation of the primitive heart tube, 
with subsequent early and late consequences for fetal car-
diac development.
Pregestational diabetes mellitus has also been associ-
ated with nonspecific embryopathy, because increased risks 
of noncardiac defects have also been reported.11 In our study, 
however, associations with maternal pregestational diabetes 
mellitus were considerably stronger for cardiac defects than 
for noncardiac defects, implying that the developing heart 
could be more vulnerable to hyperglycemia than the other 
organs.
The use of information on initial antidiabetic treat-
ment and timing of disease onset helped to correct misclas-
sification of type 1 and type 2 diabetes mellitus based on 
ICD codes from the National Patient Register. Our cohort 
included only pregnancies ending in a live birth, which could 
potentially have induced selection bias if diabetic women 
were more likely than nondiabetic women to receive fetal 
echocardiography and terminate a pregnancy if the fetus had 
a CHD. Both pregestational diabetes mellitus and CHDs also 
increase the risk of stillbirth.2 However, sensitivity analyses 
suggested that missing information on CHD in terminated 
pregnancies did not produce substantial selection bias. 
Adjustment of the association between CHD and diabetes 
mellitus for known potential confounders had little effect, 
and investigating unknown common factors for maternal 
diabetes mellitus and CHD (inverse examination of CHD 
and later onset of diabetes mellitus) suggested the absence of 
strong unknown confounders. Finally, the higher CHD risk 
in offspring of women with pregestational diabetes mellitus 
could not be explained by the use of antidiabetic medications 
in very early pregnancy.
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Conclusions
Maternal pregestational diabetes mellitus (type 1 and type 
2) was associated with a 4-fold increased offspring CHD 
risk, and this increased risk was stable over 34 years. Single 
maternal episodes of acute diabetic complications preges-
tation were associated with even higher risks of offspring 
CHD, suggesting a role for glucose in the causal pathway. 
The offspring of diabetic women had similar risks of most 
types of CHDs, suggesting that maternal diabetes mellitus 
impacts general cardiac development very early in embryo-
genesis. The increased risk of CHDs greatly exceeded the 
increased risk of noncardiac defects associated with mater-
nal diabetes mellitus.
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In this cohort of 2 million births over a 34-year period, maternal pregestational diabetes mellitus (both types 1 and 2) was 
associated with a 4-fold increase in offspring risk of congenital heart defects (CHDs), whereas gestational diabetes mellitus 
was only weakly associated with offspring CHD risk. In recent years, prenatal care has improved and awareness of optimal 
glucose regulation before pregnancy has increased. However, our study results suggest that this improved care has not dimin-
ished the risk of offspring CHD for diabetic mothers. The CHD risk associated with maternal diabetes mellitus changed very 
little over 34 years, and, among the offspring of diabetic mothers, 75% of CHD cases could be attributed to maternal dia-
betes mellitus. Maternal pregestational diabetes mellitus was associated with an increased risk of all CHD subtypes, with a 
higher risk for cardiac outflow defects. Almost 40% of women with pregestational diabetes mellitus had experienced diabetic 
complications, but only women with acute complications or multiple complications had higher offspring CHD risks than 
women without diabetic complications. Women with pregestational acute diabetic complications (coma, ketoacidosis) had 
an almost 8-fold increase in CHD risk in comparison with nondiabetic women. The higher CHD risk in offspring of women 
with pregestational diabetes mellitus could not be explained by the use antidiabetic medications very early in pregnancy. 
Our findings suggest that high glucose levels very early in pregnancy may be involved in abnormal fetal heart development. 
Optimal glucose regulation before pregnancy does not appear to eliminate the baseline risk of cardiac defects in infants 
whose mothers have pregestational diabetes mellitus.
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